Iqvia Holdings Inc.




Biotechnology & Medical Research

Market Closed - Nyse 04:00:02 2023-12-08 pm EST Intraday chart for Iqvia Holdings Inc. 5-day change 1st Jan Change
215.28 USD +0.13% -0.75% +5.07%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Transcript : IQVIA Holdings Inc. - Special Call CI
Iqvia Holdings Insider Sold Shares Worth $2,807,472, According to a Recent SEC Filing MT
Let's party like it's 2021
ANALYST RECOMMENDATIONS : Adobe, Broadcom, Comcast, Fair Isaac, Salesforce...
Will Powell deliver an early Christmas present?
ANALYST RECOMMENDATIONS : Abbvie, Boeing, IBM, Lululemon Athletica, Meta Platforms...
Transcript : IQVIA Holdings Inc. Presents at The 6th Annual Evercore ISI HealthCONx Conference, Nov-29-2023 10:50 AM CI
Not good enough!
ANALYST RECOMMENDATIONS : Best Buy, Glencore, Lowe's, Nvidia, Clorox...
Palantir Technologies-Led Group Wins Contract to Create Federated Data Platform, NHS England Says MT
IQVIA Unit Plans $500 Million Senior Notes Offering MT
JPMorgan Cuts Price Target on IQVIA Holdings to $239 From $262, Maintains Overweight Rating MT
Transcript : IQVIA Holdings Inc. - Special Call CI
Big tech saves the day
ANALYST RECOMMENDATIONS : Airbnb, Apple, Best Buy, Diageo, Tesla...
Guggenheim Adjusts Price Target on IQVIA to $220 From $253, Maintains Buy Rating MT
North American Morning Briefing : S&P 500 Futures -2- DJ
Barclays Adjusts IQVIA Holdings' Price Target to $215 From $245, Keeps Overweight Rating MT
UBS Adjusts IQVIA Holdings' Price Target to $240 From $265, Keeps Buy Rating MT
Deutsche Bank Adjusts IQVIA Holdings Price Target to $240 From $252, Maintains Buy Rating MT
Baird Downgrades IQVIA to Neutral From Outperform, Adjusts Price Target to $202 From $248 MT
Health Care Up Amid Mixed Earnings -- Health Care Roundup DJ
Transcript : IQVIA Holdings Inc., Q3 2023 Earnings Call, Nov 01, 2023 CI
Sector Update: Health Care MT
Sector Update: Health Care Stocks Decline Premarket Wednesday MT
Chart Iqvia Holdings Inc.
More charts
Iqvia Holdings Inc. is one of the world's leading companies specializing in information, analytics, research and healthcare services based on technology solutions. Net sales break down by activity as follows: - development of contract research and clinical development solutions and services (54.5%): helping biopharmaceutical companies, medical researchers and healthcare professionals optimize their clinical studies, develop new therapeutic classes, identify treatment needs and assess the efficacy of pharmaceuticals with a view to improving clinical and scientific outcomes; - development of technology and analytics solutions (39.9%): services related to information, analysis, strategic consulting, marketing studies and short-term healthcare-market studies, business processes outsourcing, and management of medical-administrative databases, all aimed at optimizing the performance and commercial strategies of pharmaceutical companies and health workers; - integrated services (5.6%): development and implementation of customized solutions and customer engagement programs, healthcare services, scientific and medical services, etc. Net sales are distributed geographically as follows: Americas (49.4%), Europe and Africa (31.4%) and Asia/Pacific (19.2%).
More about the company
Trading Rating :
Investor Rating :
ESG Refinitiv :
More Ratings
Mean consensus
Number of Analysts
Last Close Price
Average target price
Spread / Average Target
  1. Stock
  2. Equities
  3. Stock Iqvia Holdings Inc. - Nyse
  4. News Iqvia Holdings Inc.
  5. Citigroup Adjusts IQVIA Holdings' Price Target to $225 From $200, Keeps Neutral Rating
Discover our Free Content to Help You Better Understand the Stock Market.
100% Free Registration